Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

35.85 -0.20 (-0.55%)
Streaming Delayed Price Updated: 3:52 PM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What Analysts Are Saying About Crinetics Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals ↗
 
Via Benzinga
News headline image
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals ↗
 
Via Benzinga
News headline image
17 Analysts Have This To Say About Crinetics Pharmaceuticals ↗
 
Via Benzinga
News headline image
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
18 Analysts Have This To Say About Crinetics Pharmaceuticals ↗
 
Via Benzinga
News headline image
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ↗
CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-Care 
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
7 Biotech Stocks to Boost Your Portfolio to Peak Health ↗
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
Via InvestorPlace
News headline image
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives 
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.